Each TruGlif tablet contains 10 mg or 25 mg of Empagliflozin
Description:
TruGlif tablets contain empagliflozin, an orally active inhibitor of the Sodium-Glucose Co-Transporter 2 (SGLT2).
Indications:
TruGlif is indicated:
• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
Limitation of Use:
Not for the treatment of type 1 diabetes mellitus and/or diabetic ketoacidosis.
Dosage:
The recommended dose of TruGlif is 10 mg once daily in the morning, taken with or without food. In individuals tolerating TruGlif, the dose may be increased up to 25 mg or as directed by the physician.
Presentations:
TruGlif Tablets 10 mg & 25 mg are available in pack of 14’s
